[PharmaEssentia] Notice of Completion of Patient Enrollment for Phase 3 Trial
NQ Score
83/100
N1 Content Completeness
5
AI Summary (NQ-processed)
PharmaEssentia completed patient enrollment for its Phase 3 trial of P1101 for myelofibrosis.
AI Analysis
Frequently Asked Questions
- Q: How many subjects in the trial?
- A: 160 subjects.
- Q: When will it finish?
- A: Scheduled for 2027.
- Q: What is the drug used for?
- A: Treating myelofibrosis.